Trade RxSight, Inc. - RXST CFD

Trading Conditions

• Spread: 0.20
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 52.78
• Open: 51.23
• 1-Year Change: 192.24%
• Day's Range: 50.35 - 51.93

RxSight, Inc. Company profile

About Rxsight Inc

RxSight, Inc. is a commercial-stage medical technology company. The Company is engaged in improving the vision of patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system), comprised of its RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Its LAL is made of photosensitive material that changes shape in response to patterns of ultraviolet (UV) light generated by its LDD. Its RxSight system helps surgeon to performs a standard cataract procedure to implant the LAL, and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes. Alternative IOL technologies, are not adjustable following the surgery and therefore require patients to make pre-operative choices about their visual preferences.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rxsight Inc revenues increased 54% to $22.6M. Net loss applicable to common stockholders totaled $48.7M vs. income of $3.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Change in fair value of warrants decrease of 96% to $2.7M (income), Selling, general and administrative - B increase from $15.1M to $31.2M